Goldman Sachs Downgrades American Renal Associates (ARA) to Sell
Tweet
Share
E-mailGet Alerts ARA Hot Sheet
Price: $11.52 --0%
Rating Summary:
2 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 14 | New: 17
Rating Summary:
2 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 14 | New: 17
Join SI Premium – FREE
Goldman Sachs downgraded American Renal Associates (NYSE: ARA) from Neutral to Sell with a price target of $22.
For an analyst ratings summary and ratings history on American Renal Associates click here. For more ratings news on American Renal Associates click here.
Shares of American Renal Associates closed at $24.10 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS Downgrades Applus Services SA (APPS:SM) to Neutral
- Barclays Downgrades The Duckhorn Portfolio, Inc. (NAPA) to Equalweight
- UBS Downgrades SSP Group Plc. (SSPG:LN) (SSPPF) to Neutral
Create E-mail Alert Related Categories
DowngradesRelated Entities
Goldman SachsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
